PRF Technologies Ltd. (PRFX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2
First IPO Date
September 01, 2020
| Name | Title | Pay | Year Born |
| Efraim Cohen-Arazi | Interim CEO & Director | 0 | 1955 |
| Rita Keynan | Vice President of Pharmaceutical Operations | 287,000 | 1969 |
| Ehud Geller | Executive Chairman | 297,000 | N/A |
| Sigal Aviel | Chief Operating Officer | 341,000 | 1964 |
| Eyal Broder | Chief Financial Officer | 353,000 | 1971 |
| Stephen A. Cooper | Executive Vice President of Development | 0 | N/A |
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.